Medical cannabis is effective for treating a number of debilitating conditions. States with access to medical cannabis show a 25% drop in opioid overdose mortality rates. However, medical cannabis is not legal for virtually all Texans; approximately .005 percent of Texans could qualify for access under the current Texas law. Only one condition is served by the Texas Compassionate Use program, which also limits the plant’s therapeutic value and how specialists are allowed to prescribe to patients.
You can find out more about the limited cannabis medical program in Texas here – https://www.informedtexas.org/compassionate-use-program/
Find out who your Texas State Senator and Texas State Representatives are here – http://www.fyi.legis.state.tx.us/Home.aspx
PTSD – Cannabis is associated with reductions in PTSD symptoms in some patients. Greater than 75% reduction in CAPS symptom scores were reported when patients were using cannabis compared to when they were not. – George R. Greer, Charles S. Grob, Adam L. Halberstadt. “PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program”. Journal of Psychoactive Drugs, 2014; 46 (1): 73
Cancer – All cancer or anti-cancer treatment-related symptoms, including nausea, vomiting, mood disorders, fatigue, weight loss, anorexia, constipation, sexual function, sleep disorders, itching, and pain had significant improvement. The symptom score (symptomatic relief) was improved in 32.1%. – Bar-Sela, Vorobeichik, Drawsheh, Omer, Goldberg, and Muller. “The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care”. Evidence-Based Complementary and Alternative Medicine, 2013
Chron’s Disease – THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn’s disease, compared with placebo, without side effects. Subjects receiving cannabis reported improved appetite and sleep. – NaftaliI, Bar-Lev Schleider, Dotan, Lansky, Benjaminov, and Konikoff. “Cannabis Induces a Clinical Response in Patients With Crohn’s Disease: A Prospective Placebo-Controlled Study”. Clinical Gastroenterology and Hepatology, 2013
Chronic Pain – This study suggests that many CP patients are essentially substituting medical cannabis for opioids and other medications for CP treatment, and finding the benefit and side effect profile of cannabis to be greater than these other classes of medications. – Boehnke, Litinas, and Clauw. “Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain”. Journal of Pain, 2016
Nausea – In this clinical trial sponsored by the state of New York, “Fifty-six patients who had no improvement with standard antiemetic agents were treated and 78% demonstrated a positive response to marijuana … inhalation marijuana is an effective therapy for the treatment of nausea and vomiting due to cancer chemotherapy.” – Vinciguerra, et al., “Inhalation Marijuana as an Antiemetic for Cancer Chemotherapy,” New York State Journal of Medicine, October 1988
Alzheimer’s Disease – This study demonstrated the THC molecule can directly impact Alzheimer’s disease pathology. It is noteworthy that THC is a considerably more effective inhibitor of AChE-induced Aβ deposition than the approved drugs for Alzheimer’s disease treatment, donepezil and tacrine, which reduced Aβ aggregation by only 22% and 7%, respectively, at twice the concentration used in our studies. Therefore, AChE inhibitors such as THC and its analogues may provide an improved therapeutic for Alzheimer’s disease simultaneously treating both the symptoms and progression of Alzheimer’s disease. – Eubanks, Rogers, Beuscher, Koob, Olson, Dickerson, and Janda. “A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology”. National Institute of Health, 2016
ALS (Amyotrophic lateral sclerosis) – Preclinical models indicate that cannabinoids may hold the potential to delay ALS progression, lending support to anecdotal reports by some patients that cannabinoids may be efficacious in moderating the disease’s development and in alleviating certain ALS-related symptoms such as pain, appetite loss, spasticity, depression and drooling. – Amtmann et al. “Survey of cannabis use in patients with amyotrophic lateral sclerosis”. The American Journal of Hospice and Palliative Care, 2006
Multiple Sclerosis – In this long-term follow-up of a clinical trial of a marijuana-based oral spray, patients were followed for as much as 82 weeks. The marijuana spray demonstrated long-term relief of spasticity, pain, and bladder issues related to MS, “without unacceptable adverse effects. – Wade, et al., “Long-Term Use of a Cannabis-Based Medicine in the Treatment of Spasticity and Other Symptoms in Multiple Sclerosis” Multiple Sclerosis, 2006
Glaucoma – “In a number of studies of healthy adults and glaucoma pressure, IOP (intra-ocular pressure) was reduced by an average of 25% after smoking a marijuana cigarette that contained approximately 2% THC — a reduction as good as that observed with most other medications available today.” – J.E. Joy, S.J. Watson, and J.A. Benson, “Marijuana and Medicine: Assessing the Science Base”. National Academy Press, 1999
Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. States that have medical cannabis laws have a 24.8% drop in opiate overdose after year 2 of the implementation of the medical cannabis laws and a 33+% drop by year 5. – Marcus Bachhuber, eta al., “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010” JAMA Intern Med. doi:10.1001/jamainternmed.2014.4005. Published online August 25, 2014.
How many Texans have access to TCUP? – It is estimated there are about 150,000 Texans who have intractable epilepsy. The population of Texas is an estimated 28.3 million. Therefore, 0.005% of Texans have access to medical cannabis.